Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.43 |
| ▸ | CDK2 | P24941 | 2/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.43 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931080 | 0.93 | IRAK1 (0.40) | CHEK1CCNA2CDK2CCNA1IRAK1 | |
| SCHEMBL14516628 | 0.91 | CHEK1 (0.35) | CHEK1CCNA2CDK2CCNA1IRAK1 | |
| SCHEMBL14561897 | 0.87 | TRPV3 (0.36) | CHEK1CCNA2CDK2CCNA1USP30 | |
| SCHEMBL11931623 | 0.87 | ALDH1A1 (0.35) | PIK3CD | |
| SCHEMBL11931624 | 0.87 | PIK3CD (0.32) | CHEK1CCNA2CDK2CCNA1PIK3CD | |
| SCHEMBL16784395 | 0.87 | CHEK1 (0.59) | CHEK1CCNA2CDK2CCNA1 | |
| SCHEMBL11931626 | 0.85 | PIK3CD (0.32) | CHEK1CCNA2CDK2CCNA1PIK3CD | |
| SCHEMBL11931350 | 0.84 | IRAK1 (0.43) | CHEK1CCNA2CDK2CCNA1IRAK1 | |
| SCHEMBL14516630 | 0.84 | KDM4E (0.34) | IRAK1USP30PIK3CDGPR119KDM5A | |
| SCHEMBL13794295 | 0.84 | PIK3CD (0.32) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-04-12 | — | — | US | disclosed |
| US-7196092-B2 | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors | SCHERING CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082900-A1 | Methods for inhibiting protein kinases | PIM1, AURKC, PIM3 | CHEK1 8/4885CCNA2 1270/4885CDK2 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.